SMARCD1 and central nervous system cancer: Namely, 14 samples of low-grade glioma (LGG, WHO I and II) tissues, 15 samples of primary high-grade glioma (HGG, WHO III and IV) tissues, and 8 samples of secondary high-grade glioma tissues were taken to analyze the relative expression of Smarcd1.